Malin, which intends to list on the Irish stock exchange later this month, has agreed to pay $18 million (€16.5 million) for an initial 41 per cent in Serenus Biotherapeutics. Depending on how Serenus performs, Malin will raise its shareholding in the company to 76 per cent for an additional $25 million.
Martin will become chairman of Serenus as part of the investment. Serenus is developing treatment for chronic and infectious diseases and plans to concentrate on the African...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team